p53 Expression and Clinical Outcome in Prostate Cancer

British Journal of Urology

Volumn 72, Issue 5, 1993, Pages 778-781

  THOMAS, D J ^a   ROBINSON, M ^a   KING, P ^a   HASAN, T ^a   CHARLTON, R ^a   MARTIN, J ^a   CARR, T W ^a   NEAL, D E ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGE; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN P53; SUPPORT, NON-U.S. GOV'T; SURVIVAL RATE;

EID: 0027139144     PISSN: 00071331     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.1993.tb16267.x     Document Type: Article

References (13)

1. Allelic loss of chromosomes 16q and 10q in human prostate cancer
2. p53 expression in breast cancer
3. Relation between p53 overexpression and established prognostic factors in breast cancer
4. Alterations of the p53 gene are associated with the progression of a human prostate carcinoma
5. p53 immunostaining as a marker of malignant disease in diagnostic cytopathology
6. Flow cytometry using paraffin‐embedded tissue: five years on
7. Wild‐type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles
8. p53, c‐erbB‐2 and the epidermal growth factor receptor in the benign and malignant prostate
9. Mutations in the p53 gene occur in diverse human tumour types
10. p53 mutations in colon cancer
11. Expression of the nuclear oncogene p53 in colon tumours
12. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation
13. Expression of mutant p53, c‐erbB‐2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder